(PDF) Letter: CYP2C19 Polymorphisms and Exacerbation of

Letter: CYP2C19 Polymorphisms and Exacerbation of Rabeprazole's Effects on Celecoxib-Induced Small Bowel Injury-Authors' Reply

Alimentary Pharmacology and Therapeutics - United Kingdom

doi 10.1111/apt.14264

Full Text

Abstract

Available in full text

Categories

Gastroenterology

Date

September 7, 2017

Authors

Publisher

Wiley

Related search

Letter: CYP2C19 Polymorphisms and Exacerbation of Rabeprazole's Effects on Celecoxib-Induced Small Bowel Injury

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

The Influence of CYP2C19 Polymorphisms on Exacerbating Effect of Rabeprazole in Celecoxib-Induced Small Bowel Injury

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Autoimmune Hepatitis-Drug-Induced Liver Injury Must Always Be Excluded. Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Hydration and Contrast-Induced Kidney Injury – Authors' Reply

English

Letter: Phenotype and Natural History of Elderly Onset Inflammatory Bowel Disease-Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Causes of Fatigue in Inflammatory Bowel Disease Remain Uncertain - Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Vedolizumab for Autoimmune Liver Disease Associated Inflammatory Bowel Disease-Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Screening for Adrenal Suppression in Paediatric Inflammatory Bowel Disease - Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Letter: Infliximab Therapy for Patients With Inflammatory Bowel Disease - Some Unanswered Questions. Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English